LabCompass

Bradley Hittle

Medicine · The Ohio State University

Mid career · publishing since 2008Rising activity

Publications

35

Citations

268

Est. group size

~5

Recurring co-author estimate

Active years

18

Publishing since 2008

Research summary
AI-generated

Bradley Hittle's work focuses on developing automated and scalable methods for producing induced pluripotent stem cells (iPSCs, which are adult cells reprogrammed into a stem-cell-like state) and turning them into specialized tissues, such as retinal (eye) photoreceptor cells, for potential transplant therapies. This research combines cell biology with laboratory automation and robotics to make stem cell manufacturing more consistent and efficient for clinical use. Earlier work also included contributions to software tools (GooFit) for data analysis, suggesting some background in computational methods before shifting toward stem cell manufacturing.

Induced pluripotent stem cell (iPSC) manufacturingAutomation and robotics in cell cultureRetinal organoid and photoreceptor cell generationCell therapy and regenerative medicineQuality control in biomanufacturing

Publication output has been steady over the past decade, averaging a few papers per year with a brief gap in 2022 but continued activity through 2025.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 1.8/year recently
2017: 3 publications3172018: 3 publications3182019: 2 publications192020: 2 publications202021: 3 publications321222023: 3 publications3232024: 3 publications3242025: 3 publications32526
Publishes in
  • Cytotherapy×4
  • The Laryngoscope×2
  • arXiv (Cornell University)×2
  • Journal of Translational Medicine×1
  • Clinical Simulation in Nursing×1
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile